Balchem Co. (NASDAQ:BCPC) to Post Q2 2024 Earnings of $1.06 Per Share, Sidoti Csr Forecasts

Balchem Co. (NASDAQ:BCPC) – Investment analysts at Sidoti Csr lifted their Q2 2024 earnings per share estimates for Balchem in a research report issued on Monday, May 6th. Sidoti Csr analyst K. May now expects that the basic materials company will post earnings per share of $1.06 for the quarter, up from their prior estimate of $1.00. The consensus estimate for Balchem’s current full-year earnings is $4.10 per share. Sidoti Csr also issued estimates for Balchem’s FY2025 earnings at $4.13 EPS.

Several other research firms have also issued reports on BCPC. StockNews.com lowered shares of Balchem from a “buy” rating to a “hold” rating in a research note on Thursday, April 25th. HC Wainwright boosted their target price on shares of Balchem from $167.00 to $170.00 and gave the stock a “buy” rating in a research report on Monday.

Balchem Stock Down 1.4 %

Shares of Balchem stock opened at $153.28 on Thursday. The stock has a 50-day simple moving average of $150.98 and a 200-day simple moving average of $141.30. Balchem has a 52-week low of $110.74 and a 52-week high of $159.52. The firm has a market cap of $4.97 billion, a price-to-earnings ratio of 43.30, a P/E/G ratio of 3.33 and a beta of 0.72. The company has a debt-to-equity ratio of 0.31, a current ratio of 2.61 and a quick ratio of 1.72.

Balchem (NASDAQ:BCPC) last issued its quarterly earnings results on Friday, February 16th. The basic materials company reported $0.95 earnings per share for the quarter, topping analysts’ consensus estimates of $0.93 by $0.02. The firm had revenue of $228.70 million for the quarter, compared to analysts’ expectations of $234.66 million. Balchem had a return on equity of 11.03% and a net margin of 12.35%. Balchem’s revenue was down 1.6% on a year-over-year basis. During the same quarter last year, the business posted $0.66 EPS.

Insider Buying and Selling at Balchem

In other news, CAO William A. Backus sold 9,180 shares of the business’s stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $156.37, for a total value of $1,435,476.60. Following the sale, the chief accounting officer now directly owns 12,914 shares in the company, valued at $2,019,362.18. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, CAO William A. Backus sold 9,180 shares of the company’s stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $156.37, for a total transaction of $1,435,476.60. Following the sale, the chief accounting officer now owns 12,914 shares in the company, valued at $2,019,362.18. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO William A. Backus sold 7,000 shares of the company’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $155.19, for a total value of $1,086,330.00. Following the sale, the chief accounting officer now owns 5,914 shares in the company, valued at approximately $917,793.66. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 76,630 shares of company stock valued at $11,843,249. Company insiders own 1.77% of the company’s stock.

Institutional Trading of Balchem

Institutional investors and hedge funds have recently bought and sold shares of the business. Signaturefd LLC grew its position in shares of Balchem by 123.0% in the fourth quarter. Signaturefd LLC now owns 165 shares of the basic materials company’s stock valued at $25,000 after purchasing an additional 91 shares during the last quarter. Principal Securities Inc. acquired a new stake in Balchem during the fourth quarter worth approximately $28,000. Operose Advisors LLC acquired a new stake in Balchem during the third quarter worth approximately $31,000. GAMMA Investing LLC acquired a new stake in shares of Balchem in the 4th quarter valued at $56,000. Finally, YHB Investment Advisors Inc. acquired a new stake in shares of Balchem in the 1st quarter valued at $69,000. Institutional investors own 87.91% of the company’s stock.

About Balchem

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.